By Colin Kellaher

 

Merck & Co. (MRK) on Monday said it agreed to buy Tilos Therapeutics, a privately held biopharmaceutical company developing therapeutics for the treatment of cancer, fibrosis and autoimmune diseases, for up to $773 million.

The Kenilworth, N.J., drug maker said the figure includes an upfront payment and contingent milestone payments.

Merck said Tilos is developing therapeutics targeting TGF<BETA>, a potent cytokine believed to play an important role in the development of cancer and fibrotic diseases.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

June 10, 2019 07:22 ET (11:22 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024 Plus de graphiques de la Bourse Merck
Merck (NYSE:MRK)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024 Plus de graphiques de la Bourse Merck